This invention relates to devices and methods of removing acute blockages from blood vessels. The invention especially relates to removing acute obstructions from blood vessels. Acute obstructions may include clot, misplaced devices, migrated devices, large emboli and the like. Thromboembolism occurs when part or all of a thrombus breaks away from the blood vessel wall. This clot (now called an embolus) is then carried in the direction of blood flow. An ischemic stroke may result if the clot lodges in the cerebral vasculature. A pulmonary embolism may result if the clot originates in the venous system or in the right side of the heart and lodges in a pulmonary artery or branch thereof. Clots may also develop and block vessels locally without being released in the form of an embolus—this mechanism is common in the formation of coronary blockages. The invention is particularly suited to removing clot from cerebral arteries in patients suffering acute ischemic stroke (AIS), from pulmonary arteries in patients suffering from pulmonary embolism (PE), from coronary native or graft vessels in patients suffering from myocardial infarction (MI), and from other peripheral arterial and venous vessels in which clot is causing an occlusion.
There are significant challenges associated with designing clot removal devices that can deliver high levels of performance:
There are a number of access challenges that make it difficult to deliver devices. In cases where access involves navigating the aortic arch (such as coronary or cerebral blockages) the configuration of the arch in some patients makes it difficult to position a guide catheter. These difficult arch configurations are classified as either type 2 or type 3 aortic arches with type 3 arches presenting the most difficulty. The tortuosity challenge is even more severe in the arteries approaching the brain. For example it is not unusual at the distal end of the internal carotid artery that the device will have to navigate a vessel segment with a 180° bend, a 90° bend and a 360° bend in quick succession over a few centimetres of vessel. In the case of pulmonary embolisms, access may be gained through the venous system and then through the right atrium and ventricle of the heart. The right ventricular outflow tract and pulmonary arteries are delicate vessels that can easily be damaged by inflexible or high profile devices. For these reasons it is desirable that the clot retrieval device be compatible with as low profile and flexible access and support catheters as possible.
The vasculature in the area in which the clot may be lodged is often fragile and delicate. For example neurovascular vessels are more fragile than similarly sized vessels in other parts of the body and are in a soft tissue bed. Excessive tensile forces applied on these vessels could result in perforations and hemorrhage. Pulmonary vessels are larger than those of the cerebral vasculature, but are also delicate in nature, particularly those more distal vessels.
The clot may comprise any of a range of morphologies and consistencies. Long strands of softer clot material may tend to lodge at bifurcations or trifurcations, resulting in multiple vessels being simultaneously occluded over significant lengths. More mature and organized clot material is likely to be less compressible than softer fresher clot, and under the action of blood pressure it may distend the compliant vessel in which it is lodged. Furthermore the inventors have discovered that the properties of the clot may be significantly changed by the action of the devices interacting with it. In particular compression of blood clot causes dehydration of the clot and results in a dramatic increase in both clot stiffness and coefficient of friction.
The clots may not only range in shape and consistency, but also may vary greatly in length, even in any one given area of the anatomy. For example clots occluding the middle cerebral artery of an ischemic stroke patient may range from just a few millimeters to several centimeters in length.
Stent-like clot retrievers are being increasingly used to remove clot from cerebral vessels of acute stroke patients. These are self expanding devices, similar in appearance to a stent attached to the end of a long shaft, and are advanced through a microcatheter and deployed across clot obstructions in order to trap and retrieve them. They rely on a pinning mechanism to grab the clot by trapping the clot between the self-expanding stent-like body and the vessel wall. This approach has a number of disadvantages:
A stent-like clot retriever relies on its outward radial force (RF) to retain its grip on the clot. If the RF is too low the stent-like clot retriever will lose its grip on the clot, but if the RF is too high the stent-like clot retriever may damage the vessel wall and may require too much force to withdraw. Therefore stent-like clot retrievers that have sufficient radial force to deal with all clot types may cause vessel trauma and serious patient injury, and stent-like clot retrievers that have appropriate radial force to remain atraumatic may not be able to effectively handle all clot types.
The stent-like clot retriever pinning mechanism tends to compress the trapped clot. This compressive force will tend to dehydrate the clot, which in turn tends to increase its coefficient of friction, making it more difficult to remove from the vessel.
Conventional Stent-like clot retriever designs do not retain their expanded shape very well when placed in tension in bends, due to the manner in which their strut elements are connected to one another. This can result in a loss of grip on a clot as the stent-like clot retriever is withdrawn proximally around a bend in a tortuous vessel, with the potential escape of the captured clot. This occurs because the struts of the stent-like clot retriever are placed in tension when it is retracted. This tension is due to friction between the device and the blood vessel, and is increased if an additional load is applied load such as that provided by a clot. In a bend the struts on the outside of the bend are placed in higher tension than those on the inside. In order to attain the lowest possible energy state the outside surface of the stent moves towards the inside surface of the bend, which reduces the tension in the struts, but also reduces the expanded diameter of the stent-like clot retriever.
Another disadvantage with this approach is that it relies on pinning the clot between the stent-like clot retriever and the vessel wall and thus may not restrain the clot effectively when passing a branch vessel or when passing into a vessel that is larger than the fully expanded diameter of the stent-like clot retriever.
Pinning the clot between the stent-like clot retriever and the vessel wall in order to remove it from the vessel also results in high shear forces against the side of the clot as it is removed, potentially releasing fragments of the clot. If these fragments are not retained by the device they may be released leading to further blockages in the distal vasculature.
A particular difficulty encountered when attempting to remove long clots is that conventional devices may be shorter than the clot itself. A device that is shorter than the clot is unlikely to be able to restore flow through the occluded area upon deployment, and thus the pressure gradient across the clot remains a significant impediment to its removal. Simply making such a device longer would likely render it difficult to track through tortuous anatomies and could be traumatic to the vasculature, taking more force to withdraw and potentially getting stuck and requiring surgery to remove.
For many reasons including some or all of the above limitations it is often necessary for a physician to make multiple passes with a clot retrieval device in order to fully remove an obstructive clot. However each time a clot retrieval device is withdrawn the access to the target site is lost. Thus it is necessary to re-advance a guidewire and microcatheter to access and re-cross the clot, and then remove the guidewire and advance the clot retrieval device through the microcatheter. Navigating the guidewire and microcatheter to the clot can take a considerable amount of time especially if the vessels are tortuous. This additional time and device manipulation all adds to the risks to which the patient is exposed.
The challenges described above need to be overcome for any device to provide a high level of success in removing clot, restoring flow and facilitating good patient outcomes. Existing devices do not adequately address these challenges.
According to the invention there is provided a clot retrieval device for removing occlusive clot from a blood vessel, the device comprising:
In one embodiment the outer elongate body comprises a plurality of clot receiving openings and a plurality of clot engaging regions. The clot engaging may be adapted, on engagement with clot, to urge clot towards the clot receiving openings and into the reception space between the outer elongate body and the inner elongate body,
In one case the radial force at a distal end of the device is lower than that at a middle section of the device.
The radial force at a distal end of the device may be lower than that of a middle section and a proximal section of the device.
In one embodiment the device comprises a plurality of segments and the radial force of one segment is different than the radial force of at least one other segment. The difference in radial force between the segments may be less than 20%, or less than 10%.
In one case the radial force increases along the length of the device from proximal to distal.
In another case the radial force of a mid segment is greater than the radial force of the distal segment.
In yet another case the radial force of a mid segment is greater than that of the proximal segment and the distal segment.
In one embodiment the outer body comprises a plurality of segments.
In one case a segment comprises a proximal ring of closed cells having a first radial force to which are connected at least one floating cell or leaflet having a second radial force which is less than the first radial force. The second radial force may be from 20% to 80%, or from 40% to 60% lower than the first radial force.
In one embodiment the clot inlet openings of the segments of the outer body differ along the length of the device.
In one case clot inlet openings in a proximal region of the device are smaller than clot inlet openings in a distal region of the device.
In another case the clot inlet openings in a middle section of the device are smaller than those in a more proximal and/or a more distal region of the device.
In a further case the clot inlet openings in a middle section of the device are larger than those in a more proximal and/or a more distal region of the device.
In one embodiment there is a gradient of the size of the clot inlet openings along the length of the device.
In one case the gradient increases from proximal to distal.
In another case the gradient decreases from proximal to distal.
In some embodiments the inner elongate body is tapered. The taper of the inner elongate body may be opposite to the gradient of the clot inlet openings in the outer body.
In another aspect of the invention the outer elongate member comprises a framework formed by struts and crowns and wherein proximal radiopaque markers are located at a distal end of struts which are proximally adjacent to proximal crowns.
According to the invention there is provided a clot retrieval device for removing occlusive clot from a blood vessel, the device comprising:
In this aspect of the invention the embolization risk is reduced by providing a distal net or scaffolding zone across the vessel lumen towards the distal end of the device. This scaffolding in this case is appended to both the inner or outer member or to both members, and is three dimensional in that it has depth as well as surface area. Combining the scaffolding of both inner and outer members provides a more effective filter than utilizing one member alone. In some cases fibres or fine wires are utilised to provide added scaffolding with minimal impact on device profile or deliverability.
In one embodiment the distal portion of the inner elongate body comprises a plurality of struts which are configured in a volumetric pattern.
In one case the distal portion of the inner elongate body comprises a bulged or flared framework of struts.
In one embodiment the distal end portion of the outer elongate body comprises distal struts. In one case the distal struts of the distal end portion of the outer elongate member are configured in a generally conical shape.
In one embodiment at least some of the struts comprise an attachment point, such as an eyelet, for reception of a fibre. The protective structure may include a plurality of fibres providing a distal net.
In one embodiment the outer elongate body comprises a first monolithic structure.
In one embodiment the inner elongate body comprises a second monolithic structure.
In one case wherein the inner elongate body extends proximally of a proximal end of the outer elongate body.
In one embodiment the outer elongate body comprises a plurality of clot receiving openings and a plurality of clot engaging regions, and wherein the clot engaging regions are adapted, on engagement with clot, to urge clot towards the clot receiving openings and into the reception space between the outer elongate body and the inner elongate body.
The clot engaging regions of the outer elongate body comprises scaffolding openings, the clot receiving openings being substantially larger than the scaffolding openings.
In one embodiment the outer elongate body comprises at least two longitudinally spaced-apart segments. There may be at least one hinge is provided between the segments.
The disclosed designs overcome many of the disadvantages of existing mechanical thrombectomy solutions.
Various interchangeable terms are used herein to describe those portions of the invention that are configured to engage with the clot, being generally deployed within the clot and engaging with it. These terms include “clot engaging portion”, “expandable member”, “expandable body”, “clot engaging element”; while the terms “elongate basket”, “engaging basket” and “stent basket” may also be used to describe this portion of the device.
Designs are disclosed in which a clot engaging portion of the device is configured to be expanded within an occlusive clot in a blood vessel so that the expanding engager allows the clot to migrate into a reception space within the body of the engager as the engager expands. The engager is delivered through a catheter to the site of the occlusion and is positioned within the clot. The engager is expandable at the site of the occlusion and starts to compress the clot as it is expanded. The engager surface comprises inlet openings and the inlet openings allow the clot to ‘escape’ from compression by displacing a significant portion of the clot through the inlet openings in the wall of the engager. Because a significant portion of the clot is urged through the inlet openings in the engager this minimizes compression of the clot and hence minimizes the resultant increase in the clot coefficient of friction. This also reduces the radial force on the vessel in the region of the clot which means a lesser force is required to withdraw the captured clot, which in turn means less vessel trauma and less tension on the distal vascular bed. The device is configured such that the radial force of the device acts strongly at a small diameter to engage with and grip clot, but acts softly at a larger diameter to gently contact the vessel wall are also disclosed.
The radial force profile of the device may be further tailored along the device length. For example in one embodiment of the device of this invention the radial force of the distal end of the device is lower than that of the middle section of the device. In one embodiment the radial force of the distal end of the device is lower than that of the middle and proximal sections of the device. In one embodiment of the device of this invention the device comprises a plurality of segments, and the radial force of any segment may be the same or different from the adjacent segment. In one embodiment of such a device the radial force of all the segments is balanced such that the radial force of any given segment differs by less than 20%, and more preferably by less than 10%, from the radial force of any other segment. In one embodiment of such a device the radial force of any given segment differs by less than 20%, and more preferably by less than 10%, from the radial force of an adjacent segment. In one embodiment of such a device the radial force of all the segments is tailored such that the radial force generally decreases along the length of the device from proximal to distal. In one embodiment of such a device the radial force of all the segments is tailored such that the radial force generally increases along the length of the device from proximal to distal. In another embodiment the radial force of a mid segment is greater than that of the distal segment. In another embodiment the radial force of a mid segment is greater than that of the proximal and distal segments.
The radial force of the device of this invention can be further tailored within each individual segment of the outer expandable member. In particular, a segment of the outer expandable member may comprise a proximal ring of connected closed cells of a first radial force to which are connected one or more floating cells or leaflets of a second radial force. These floating cells or leaflets are distinguished by the fact that their distal apices are not connected to a more distal portion of the device—rather they are floating or disconnected. This allows these leaflets to act as trapdoors through which clot may fall into the inner reception space of the device. They may further act as trap features which are better able to remain open and apposed to the vessel wall as the device is retracted around bends and past branch vessels, helping to retain any trapped clot. In one embodiment the second radial force is lower than the first radial force. In one embodiment the second radial force is between 20% and 80% lower than the first radial force. In a preferred embodiment the second radial force is between 40% and 60% lower than the first radial force.
Designs with dual expandable members are disclosed whereby the device comprises a first inner expandable member and a second outer expandable member the inner member being arranged substantially within the lumen of the outer member. The properties of the inner and outer members may be tailored independently of each other. The inner member may have a very different radial force to the outer member. The inner member may have a very different level of porosity to the outer member. The inner member may have a fully expanded diameter that is very different to that of the outer member. The length of the inner member may be different to that of the outer member. The shape of the struts of the inner member may be different to the shape of the struts of the outer member. There may be a clearance between the inner member and the outer member in the expanded configuration. There may be a clearance between the inner member and the outer member in the collapsed configuration. One, or both or neither of the inner and outer members may have a seam which runs substantially longitudinally along at least a portion of the wall of the member. One, or both of the inner and outer members may comprise a laser cut member, a braided member, a knitted member, an extruded member, a pultruded member, One or both of the inner and outer members may be manufactured with a process involving a laser cutting step, a braiding step, a knitting step, an extrusion step, a pultrusion step, an electropolishing step, a heat treatment step. One or both of the inner and outer members may comprise a tapered section, a flared section, a closed end section or a closed mid section. One or both members may comprise a substantially tubular or cylindrical section.
One embodiment of an inner member of this invention comprises an interconnected strut framework forming a generally tubular section, where the struts of the framework define cells or openings, and said cells or openings define the porosity of the member. This tubular section may comprise different cell patterns and a variety of cell shapes. In one embodiment there are at least two cells around the circumference of any given section through the device. In a preferred embodiment there are at least three cells around the circumference of any given section through the device. Greater numbers of cells will provide a more dense and less porous structure, which will be more capable of maintaining a flow lumen through soft clot but at the cost of device flexibility and profile. The optimum number of cells depends therefore on the consistency of the material in which the device is to be deployed and on the diameter to which the member is designed to expand. Greater diameters may require greater numbers of cells to maintain an appropriate and effective level of porosity. A cell area of less than 4.0 mm2 is desired in order to achieve an adequate degree of clot scaffolding. However a cell area of less than 0.5 mm2 may cause unwanted blood coagulation or thrombosis, making the device difficult to clean for reuse and potentially generating harmful clot fragments. Therefore a cell area of between 1.0 mm2 and 3.0 mm2 is most preferred.
An inner expandable member expanded diameter of between 0.75 mm and 2.5 mm is likely to be most suitable for neurovascular applications of the invention. An inner expandable member expanded diameter of between 0.75 mm and 1.75 mm with a 3 or 4 cell structure is most preferred.
The diameter of the generally tubular inner member may vary along its length. In one embodiment the inner member diameter has a generally conical shape. In one embodiment the inner member diameter tapers from a smaller proximal diameter to a larger distal diameter. In one embodiment the inner member diameter tapers from a larger proximal diameter to a smaller distal diameter. In one embodiment the inner member diameter tapers from a diameter of approximately 0.75 mm-1.75 mm to a diameter of approximately 1.5 mm-4.0 mm.
These dual expandable member devices have a number of benefits. (1) The inner member can be configured to provide a strong opening force to create a lumen through the clot and restore flow immediately on deployment. This flow lumen reduces the pressure gradient across the clot, making it easier to remove the clot. (2) The diameter to which the inner member expands may be tailored so as to reduce the risk of a reperfusion injury. With this embodiment the inner member expands to a diameter that is significantly smaller than the diameter of the vessel immediately adjacent to and distal of the occlusion. This small diameter inner member creates a small flow lumen across the occlusion and restricts the initial blood flow to the affected portion of the brain. This restricted blood flow ensures that the pressure applied to blood vessels immediately after flow restoration is lower than normal and this reduces the risk of bleeding in the ischemic vascular bed. Full perfusion is subsequently restored by removing the device and the clot. (3) The inner member may be configured to expand to a lesser diameter than the outer basket and to a lesser diameter than any vessel in which it is to be deployed. This means that a strong radial force may be safely exerted on the clot to open up a flow lumen, but need not be exerted on the vessel. (4) The inner member can serve to scaffold the lumen created through the clot, preventing the liberation of emboli from the clot into the resultant fast flowing bloodstream. (5) The inner member may at least partially comprise a stent and can provide a strong grip on the clot for the critical initial step of disengaging the clot from the vessel, enabling the outer basket to be configured with a low radial force. (6) The outer member may be configured to have large inlet openings so as to urge clot across the wall of the outer. The inner member on the other hand may be configured to prevent distal migration or fragmentation or embolization of clot that traverses the wall of the outer member. By configuring the outer member so as to encourage clot to traverse the wall of the outer member the device can more effectively disengage clot from the wall of the vessel while the device is also effective at preventing loss of clot material with an inner member with a shape and substructure that provides scaffolding.
The inlet openings of the outer member may be further tailored to cater for the range of clot types and sizes that may be encountered clinically. Large inlet openings are desirable for accepting clot into the inner reception space of the device for secure clot capture, but may be disadvantageous when attempting to retain a secure grip on the clot as it is retracted proximally past bends and branches. In one embodiment the inlet openings may differ along the length of the device. In one embodiment the inlet openings in a proximal region of the device are larger than the inlet openings in a distal region of the device. In one embodiment the inlet openings in a proximal region of the device are smaller than the inlet openings in a distal region of the device. In one embodiment the inlet openings in a middle section of the device are smaller than those in a more proximal and/or distal region of the device. In one embodiment the inlet openings in a middle section of the device are larger than those in a more proximal and/or distal region of the device. In one embodiment a gradient of inlet openings is provided. In one such embodiment this gradient increases from proximal to distal so that a clot that fails to enter a smaller more proximal opening may be trapped by a larger more distal opening as the device is retracted. In one such embodiment this gradient decreases from proximal to distal so that any clot entering a larger more proximal opening will not be able to exit a smaller more distal opening as the device is retracted. Such an outer member may be combined with a tapered inner member to further assist in clot demobilisation and trapping—so that a clot entering through a large proximal opening of the outer member adjacent a small diameter portion of the inner member is prevented from migrating distally along the device by the increasing diameter of the more distal portion of the tapered inner member.
Various embodiments of the invention are described in more detail below. Within these descriptions various terms for each portion of the devices may be interchangeably used as discussed previously. Each of the described embodiments are followed by a list of further qualifications (preceded by the word “wherein”) to describe even more detailed versions of the preceding headline embodiment. It is intended that any of these qualifications may be combined with any of the headline embodiments, but to maintain clarity and conciseness not all of the possible permutations have been listed.
In one embodiment of the invention the treatment apparatus comprises a clot retrieval device comprising: an elongate member, and an expandable clot engaging element configured to extend across the clot in its expanded state, the expandable clot engaging element comprising a first monolithic structure and a second monolithic structure, the first monolithic structure encircling the second monolithic structure over at least a portion of its length, the second monolithic structure comprising a proximal section, an intermediate section and a distal section, the distal section comprising an expansion.
Some optional features of this embodiment include:
In another embodiment of the invention the treatment apparatus comprises a clot retrieval device comprising: an elongate member, and an expandable clot engaging element configured to extend across the clot in its expanded state, the expandable clot engagement element comprising a proximal segment, a clot engaging segment and a distal segment, the proximal segment configured to extend proximal of the clot in use and the distal end configured to extend distal of the clot in use, the clot engaging segment configured to engage with the clot in its expanded state, the distal end comprising a fragment protection structure, the fragment protection structure comprising a plurality of struts configured in a volumetric pattern.
Some optional features of this embodiment include:
In another embodiment of the invention the treatment apparatus comprises a clot retrieval device comprising: an elongate member, and an expandable clot engaging element comprising a first tubular structure and a second tubular structure, the first tubular structure at least partially encircling the second tubular structure, the first tubular structure comprising a proximal end, a distal end, a proximal termination and a distal termination, the second tubular structure comprising a proximal end, a distal end, a proximal termination and a distal termination, the proximal termination of the first and second tubular structures being connected to the elongate member and the distal terminations of the first and second tubular structures being connected to each other.
Some optional features of this embodiment include:
In another embodiment of the invention the treatment apparatus comprises a clot retrieval device comprising: an elongate member, and an expandable clot engaging element comprising a first tubular structure and a second tubular structure, the first tubular structure at least partially encircling the second tubular structure, the first tubular structure and the second tubular structure connected to a distal end of the elongate member at a connection point, the first tubular structure comprising a first proximal connecting strut and a first connector element, the second tubular structure comprising a second proximal connecting strut and a second connector element, the first connector element encircling the second connector element at the connection point.
Some optional features of this embodiment include:
In another embodiment of the invention the treatment apparatus comprises a clot retrieval device comprising: an elongate member, and an expandable clot engaging element configured to extend across the clot in its expanded state, the expandable clot engagement element comprising a first luminal structure and a second luminal structure, the first luminal structure being larger in diameter than said second luminal structure, the distal end of said first luminal structure comprising a plurality of struts converging towards the axis of the first luminal structure, the distal end of said second luminal structure comprising a plurality of struts diverging away from the axis of said second luminal structure.
Some optional features of this embodiment include:
In another embodiment of the invention the treatment apparatus comprises a clot retrieval device comprising: an elongate member, and a clot engaging element comprising a collapsed delivery state and an expanded clot engaging state, the clot engaging element configured to extend across the clot in its expanded state, the clot engaging element comprising a proximal section, an intermediate section and a distal section, the intermediate section comprising a luminal structure and the distal section comprising an expansion region.
Some optional features of this embodiment include:
In another embodiment of the invention the treatment apparatus comprises a device for removing clot from a blood vessel comprising: an elongate member, and an expandable clot engaging element configured to extend across the clot in its expanded state, the expandable clot engagement element comprising a first luminal structure and a second luminal structure, the first luminal structure being larger in diameter than said second luminal structure and encircling at least a portion of the second luminal structure, the second luminal structure comprising a clot capture structure at its distal end, the clot capture structure comprising a flared section.
Some optional features of this embodiment include:
In another embodiment of the invention the treatment apparatus comprises a clot retrieval device comprising an elongate member, a first expandable member and a second expandable member; both expandable members having a proximal section, a body section, and a distal section, the body section of the first expandable member in the freely expanded state being larger in diameter than that of the second expandable member in the freely expanded state, and the proximal section of the first expandable member being distal of the proximal section of the second expandable member.
Some optional features of this embodiment include:
A method of using a clot retrieval device to retrieve a clot from a vessel, said clot retrieval device comprising an expandable body and an elongate shaft, said method comprising: delivering the device through a microcatheter to a target site, retracting the microcatheter to deploy the device at least partially within or beneath the clot, expanding a proximal section of the expandable member within a proximal section of the clot to a diameter smaller than that of the vessel, expanding a distal section of the expandable member distal of the clot to a diameter substantially equal to that of the vessel, withdrawing the device and clot proximally and removing both from the patient.
Some optional features of this embodiment include:
The invention will be more clearly understood from the following description of some embodiments thereof, given by way of example only, with reference to the accompanying drawings, in which:
Specific embodiments of the present invention are now described in detail with reference to the figures, wherein identical reference numbers indicate identical or functionality similar elements. The terms “distal” or “proximal” are used in the following description with respect to a position or direction relative to the treating physician. “Distal” or “distally” are a position distant from or in a direction away from the physician. “Proximal” or “proximally” or “proximate” are a position near or in a direction toward the physician.
Accessing cerebral, coronary and pulmonary vessels involves the use of a number of commercially available products and conventional procedural steps. Access products such as guidewires, guide catheters, angiographic catheters and microcatheters are described elsewhere and are regularly used in cath lab procedures. It is assumed in the descriptions below that these products and methods are employed in conjunction with the device and methods of this invention and do not need to be described in detail.
The following detailed description is merely exemplary in nature and is not intended to limit the invention or the application and uses of the invention. Although the description of the invention is in many cases in the context of treatment of intracranial arteries, the invention may also be used in other body passageways as previously described.
A common theme across many of the disclosed designs is a dual layer construction in which the device comprises an outer expandable member within which runs an inner expandable member, both members being directly or indirectly connected to an elongate shaft, and a distal net or scaffold configured at the distal end of the device to prevent the escape of clot fragments. This distal net may be appended to either the shaft, the inner or the outer members or to several of these. A range of designs are envisaged for each of these elements as described throughout this document, and it is intended that any of these elements could be used in conjunction with any other element, although to avoid repetition they are not shown in every possible combination.
Both the inner and outer expandable members are desirably made from a material capable of recovering its shape automatically once released from a highly strained delivery configuration. A superelastic material such as Nitinol or an alloy of similar properties is particularly suitable. The material could be in many forms such as wire or strip or sheet or tube. A particularly suitable manufacturing process is to laser cut a Nitinol tube and then heat set and electropolish the resultant structure to create a framework of struts and connecting elements. This framework can be any of a huge range of shapes as disclosed herein and may be rendered visible under fluoroscopy through the addition of alloying elements (such as Platinum for example) or through a variety of other coatings or marker bands.
The inner expandable member may in some cases form a generally tubular structure and is ideally configured to expand to a lesser diameter than that of the smallest vessel in which it is intended to be used. In the case of a generally non-tapered inner member this diameter is typically less than 50% that of the outer expandable member and may be as low as 20% or less of the outer member diameter.
The closed end of the distal expandable segment 28 prevents the egress of clot or clot fragments that have entered the reception space 11 between the inner and outer members. The expanded distal struts 10 of the inner member act as an additional three dimensional filter in combination with the closed distal end of the outer member 2 to further prevent the egress of clot or clot fragments. In certain embodiments this distal section may comprise fibre attachment points such as eyelets 87 or other fibre attachment features and fibres may be connected to the distal section at these attachment points to create a distal net.
The inner and outer members are preferably made of a super-elastic or pseudo-elastic material such as Nitinol or another such alloy with a high recoverable strain. Shaft 6 may be a tapered wire shaft, and may be made of stainless steel, MP35N, Nitinol or other material of a suitably high modulus and tensile strength. Shaft 6 has a coil 4 adjacent its distal end and proximal of the outer member 2 and inner expandable member 3. This coil 4 may be metallic and may be formed from stainless steel or from a more radiopaque material such as platinum or gold for example or an alloy of such a material. In another embodiment the coil 4 may be coated with a low friction material or have a polymeric jacket positioned on the outer surface of the coil.
Each expandable segment 26 comprises a proximal ring of connected struts 84 and a plurality of distal “leaflets” 85. Each leaflet comprises a pair of struts terminating in a distal crown 86 to which no further elements are connected. The connected ring of struts 84 provides the segment with the radial force to open and expand when deployed under a clot. The leaflets 85 are able to deflect (like trapdoors) to allow clot to slide into the inlet openings 22. The combination of leaflets and hinge elements 29 allows the device to retain its expanded shape and remain in contact with the vessel wall as the device is retracted around bends and past branch vessels. During this retraction process the leaflets act to prevent clot from escaping from the device, closing the trapdoor and gently contacting the vessel wall.
One or more expandable members may comprise marker bands or radiopaque features such as gold or platinum marker or coils. In this embodiment three radiopaque markers 25 are shown fixed in eyelets 87 of the distal expandable member 28. The gold marker is positioned to indicate to the user the distal end of the barrel section of the outer member to aid in accuracy of deployment.
The outer member 2 and the inner expandable member 3 are joined at the proximal and distal ends during assembly thereof to minimise tension within the members during use, the length of the outer member 2 should be substantially the same as the length of the inner expandable member 3 in the freely expanded configuration and the loaded configuration. The expanded struts 10 of the inner expandable member 3 elongate during loading so that the lengths of the inner and outer members are equal when fully loaded in a microcatheter. Length differentials between the inner expandable member 3 and the outer member 2 can still occur when the device is deployed in a small vessel or during the loading or deployment process. The coil 18 at the distal end of the inner expandable member 3 can accommodate minor length differentials by stretching without applying significant tensile or compressive forces to the device. In another embodiment this coil could be formed separately to the inner expandable member 3 and then be assembled to it. The coil could be formed from a stainless steel material, a polymer or from a more radiopaque metal such as gold or platinum or an alloy of such a material. The coil could also be replaced with a longitudinal length of an elastic material such as a low modulus polymer or elastomer.
The microcatheter 102 is retracted while the position of device 110 is maintained static to deploy the clot retrieval device 110 across the clot 101. On deployment, the distal end 120 of the device 110 is preferably positioned distal of the clot 101. The device 110 expands so that the outer member 121 engages with the occlusive clot to facilitate clot retrieval from the vessel, and the inner tubular member 122 expands to provide a flow channel to restore blood flow in a controlled manner through the occlusive clot 101 to the vasculature distal of the occlusion. The inner channel 122 may also engage the clot 101 to provide additional grip for dislodgement. The device 110 may be allowed to incubate for a period of time within the clot 101 if desired, as controlled flow has been restored through the inner tubular member 122.
Retracting the device 110 dislodges the clot 101 from its position in the artery 100 and further withdrawal of the device retrieves the clot 101 until it can be retrieved into the guide catheter or introducer sheath 130.
It will be apparent from the foregoing description that, while particular embodiments of the present invention have been illustrated and described, various modifications can be made without departing from the spirit and scope of the invention. For example, while the embodiments described herein refer to particular features, the invention includes embodiments having different combinations of features. The invention also includes embodiments that do not include all of the specific features described.
The invention is not limited to the embodiments hereinbefore described which may be varied in construction and detail.
This is a U.S. national phase application under 35 U.S.C. § 371 of International Patent Application No. PCT/EP2017/072030, filed Sep. 1, 2017, and claims benefit of priority to U.S. Provisional Patent Application No. 62/383,905, filed Sep. 6, 2016. The entire contents of these applications are hereby incorporated by reference.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/EP2017/072030 | 9/1/2017 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2018/046408 | 3/15/2018 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
2828147 | Peiffer | Mar 1958 | A |
3361460 | Jansen | Jan 1968 | A |
4455717 | Gray | Jun 1984 | A |
4611594 | Grayhack et al. | Sep 1986 | A |
4612931 | Dormia | Sep 1986 | A |
4793348 | Palmaz | Dec 1988 | A |
4873978 | Ginsburg | Oct 1989 | A |
5011488 | Ginsburg | Apr 1991 | A |
5084065 | Weldon et al. | Jan 1992 | A |
5092839 | Kipperman | Mar 1992 | A |
5100423 | Fearnot | Mar 1992 | A |
5102415 | Guenther et al. | Apr 1992 | A |
5108419 | Reger et al. | Apr 1992 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5163951 | Pinchuk et al. | Nov 1992 | A |
5171233 | Amplatz et al. | Dec 1992 | A |
5171259 | Inoue | Dec 1992 | A |
5217441 | Shichman | Jun 1993 | A |
5234437 | Sepetka | Aug 1993 | A |
5236447 | Kubo et al. | Aug 1993 | A |
5330482 | Gibbs et al. | Jul 1994 | A |
5387219 | Rappe | Feb 1995 | A |
5387226 | Miraki | Feb 1995 | A |
5449372 | Schmaltz et al. | Sep 1995 | A |
5499985 | Hein et al. | Mar 1996 | A |
5538512 | Zenzon et al. | Jul 1996 | A |
5538515 | Kafry et al. | Jul 1996 | A |
5549626 | Miller et al. | Aug 1996 | A |
5558652 | Henke | Sep 1996 | A |
5609627 | Goicoechea et al. | Mar 1997 | A |
5624461 | Mariant | Apr 1997 | A |
5639277 | Mariant et al. | Jun 1997 | A |
5639278 | Dereume et al. | Jun 1997 | A |
5645558 | Horton | Jul 1997 | A |
5653605 | Woehl et al. | Aug 1997 | A |
5658296 | Bates et al. | Aug 1997 | A |
5665117 | Rhodes | Sep 1997 | A |
5695519 | Summers et al. | Dec 1997 | A |
5709704 | Nott et al. | Jan 1998 | A |
5713853 | Clark et al. | Feb 1998 | A |
5769871 | Mers Kelly et al. | Jun 1998 | A |
5769884 | Solovay | Jun 1998 | A |
5779686 | Sato et al. | Jul 1998 | A |
5779716 | Cano et al. | Jul 1998 | A |
5800519 | Sandock | Sep 1998 | A |
5810874 | Lefebvre | Sep 1998 | A |
5814064 | Daniel et al. | Sep 1998 | A |
5827304 | Hart | Oct 1998 | A |
5853422 | Huebsch et al. | Dec 1998 | A |
5855598 | Pinchuk | Jan 1999 | A |
5893869 | Barnhart et al. | Apr 1999 | A |
5895398 | Wensel et al. | Apr 1999 | A |
5897567 | Ressemann et al. | Apr 1999 | A |
5904698 | Thomas et al. | May 1999 | A |
5911702 | Romley et al. | Jun 1999 | A |
5911725 | Boury | Jun 1999 | A |
5919126 | Armini | Jul 1999 | A |
5931509 | Bartholomew | Aug 1999 | A |
5935139 | Bates | Aug 1999 | A |
5947995 | Samuels | Sep 1999 | A |
6063113 | Kavteladze et al. | May 2000 | A |
6066149 | Samson et al. | May 2000 | A |
6066158 | Engelson et al. | May 2000 | A |
6093196 | Okada | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6096053 | Bates | Aug 2000 | A |
6099534 | Bates et al. | Aug 2000 | A |
6099559 | Nolting | Aug 2000 | A |
6102932 | Kurz | Aug 2000 | A |
6106548 | Roubin et al. | Aug 2000 | A |
6129739 | Khosravi | Oct 2000 | A |
6143022 | Shull et al. | Nov 2000 | A |
6146404 | Kim et al. | Nov 2000 | A |
6156064 | Chouinard | Dec 2000 | A |
6165194 | Denardo | Dec 2000 | A |
6165199 | Barbut | Dec 2000 | A |
6168604 | Cano | Jan 2001 | B1 |
6168622 | Mazzocchi | Jan 2001 | B1 |
6174318 | Bates et al. | Jan 2001 | B1 |
6179861 | Khosravi et al. | Jan 2001 | B1 |
6203561 | Ramee et al. | Mar 2001 | B1 |
6214026 | Lepak et al. | Apr 2001 | B1 |
6221006 | Dubrul et al. | Apr 2001 | B1 |
6231597 | Deem et al. | May 2001 | B1 |
6238412 | Dubrul et al. | May 2001 | B1 |
6245012 | Kleshinski | Jun 2001 | B1 |
6245087 | Addis | Jun 2001 | B1 |
6251122 | Tsukernik | Jun 2001 | B1 |
6254571 | Hart | Jul 2001 | B1 |
6264663 | Cano | Jul 2001 | B1 |
6267777 | Bosma et al. | Jul 2001 | B1 |
6290710 | Cryer et al. | Sep 2001 | B1 |
6312444 | Barbut | Nov 2001 | B1 |
6315778 | Gambale et al. | Nov 2001 | B1 |
6325815 | Kusleika et al. | Dec 2001 | B1 |
6325819 | Pavcnik et al. | Dec 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6336934 | Gilson et al. | Jan 2002 | B1 |
6346116 | Brooks et al. | Feb 2002 | B1 |
6348056 | Bates et al. | Feb 2002 | B1 |
6350271 | Kurz et al. | Feb 2002 | B1 |
6355057 | DeMarais et al. | Mar 2002 | B1 |
6361545 | Macoviak et al. | Mar 2002 | B1 |
6364895 | Greenhalgh | Apr 2002 | B1 |
6375668 | Gifford et al. | Apr 2002 | B1 |
6375670 | Greenhalgh | Apr 2002 | B1 |
6383205 | Samson et al. | May 2002 | B1 |
6383206 | Gillick et al. | May 2002 | B1 |
6391037 | Greenhalgh | May 2002 | B1 |
6402771 | Palmer et al. | Jun 2002 | B1 |
6416541 | Denardo | Jul 2002 | B2 |
6425909 | Dieck et al. | Jul 2002 | B1 |
6428558 | Jones et al. | Aug 2002 | B1 |
6432122 | Gilson et al. | Aug 2002 | B1 |
6436112 | Wensel et al. | Aug 2002 | B2 |
6458139 | Palmer et al. | Oct 2002 | B1 |
6485497 | Wensel et al. | Nov 2002 | B2 |
6485501 | Green | Nov 2002 | B1 |
6485502 | Don Michael et al. | Nov 2002 | B2 |
6488701 | Nolting et al. | Dec 2002 | B1 |
6511492 | Rosenbluth et al. | Jan 2003 | B1 |
6530935 | Wensel et al. | Mar 2003 | B2 |
6530939 | Hopkins et al. | Mar 2003 | B1 |
6540768 | Diaz et al. | Apr 2003 | B1 |
6544279 | Hopkins et al. | Apr 2003 | B1 |
6551341 | Boylan et al. | Apr 2003 | B2 |
6551342 | Shen et al. | Apr 2003 | B1 |
6575996 | Denison et al. | Jun 2003 | B1 |
6575997 | Palmer et al. | Jun 2003 | B1 |
6582448 | Boyle et al. | Jun 2003 | B1 |
6585756 | Strecker | Jul 2003 | B1 |
6589265 | Palmer et al. | Jul 2003 | B1 |
6592607 | Palmer et al. | Jul 2003 | B1 |
6592614 | Lenker et al. | Jul 2003 | B2 |
6592616 | Stack et al. | Jul 2003 | B1 |
6598265 | Lee | Jul 2003 | B2 |
6602265 | Dubrul et al. | Aug 2003 | B2 |
6602271 | Adams et al. | Aug 2003 | B2 |
6602272 | Boylan et al. | Aug 2003 | B2 |
6605102 | Mazzocchi et al. | Aug 2003 | B1 |
6610077 | Hancock et al. | Aug 2003 | B1 |
6616679 | Khosravi et al. | Sep 2003 | B1 |
6632241 | Hancock et al. | Oct 2003 | B1 |
6638245 | Miller et al. | Oct 2003 | B2 |
6638293 | Makower et al. | Oct 2003 | B1 |
6641590 | Palmer et al. | Nov 2003 | B1 |
6656218 | Denardo et al. | Dec 2003 | B1 |
6660021 | Palmer et al. | Dec 2003 | B1 |
6663650 | Sepetka et al. | Dec 2003 | B2 |
6673089 | Yassour et al. | Jan 2004 | B1 |
6685722 | Rosenbluth et al. | Feb 2004 | B1 |
6692504 | Kurz et al. | Feb 2004 | B2 |
6692508 | Wensel et al. | Feb 2004 | B2 |
6692509 | Wensel et al. | Feb 2004 | B2 |
6695858 | Dubrul et al. | Feb 2004 | B1 |
6702782 | Miller et al. | Mar 2004 | B2 |
6712834 | Yassour et al. | Mar 2004 | B2 |
6726701 | Gilson et al. | Apr 2004 | B2 |
6726703 | Broome et al. | Apr 2004 | B2 |
6730104 | Sepetka et al. | May 2004 | B1 |
6783528 | Vincent-Prestigiacomo | Aug 2004 | B2 |
6783538 | McGuckin, Jr. et al. | Aug 2004 | B2 |
6824545 | Sepetka et al. | Nov 2004 | B2 |
6855155 | Denardo et al. | Feb 2005 | B2 |
6878163 | Denardo et al. | Apr 2005 | B2 |
6890340 | Duane | May 2005 | B2 |
6913612 | Palmer et al. | Jul 2005 | B2 |
6913618 | Denardo et al. | Jul 2005 | B2 |
6939361 | Kleshinski | Sep 2005 | B1 |
6953472 | Palmer et al. | Oct 2005 | B2 |
6989019 | Mazzocchi et al. | Jan 2006 | B2 |
6989021 | Bosma et al. | Jan 2006 | B2 |
6994718 | Groothuis et al. | Feb 2006 | B2 |
7004954 | Voss et al. | Feb 2006 | B1 |
7004955 | Shen et al. | Feb 2006 | B2 |
7004956 | Palmer et al. | Feb 2006 | B2 |
7008434 | Kurz et al. | Mar 2006 | B2 |
7033376 | Tsukernik | Apr 2006 | B2 |
7041116 | Goto et al. | May 2006 | B2 |
7048758 | Boyle et al. | May 2006 | B2 |
7052500 | Bashiri et al. | May 2006 | B2 |
7058456 | Pierce | Jun 2006 | B2 |
7063707 | Bose et al. | Jun 2006 | B2 |
7083633 | Morrill et al. | Aug 2006 | B2 |
7083822 | Brightbill | Aug 2006 | B2 |
7094249 | Broome et al. | Aug 2006 | B1 |
7097653 | Freudenthal et al. | Aug 2006 | B2 |
7101380 | Khachin et al. | Sep 2006 | B2 |
7172614 | Boyle et al. | Feb 2007 | B2 |
7175655 | Molaei | Feb 2007 | B1 |
7179273 | Palmer et al. | Feb 2007 | B1 |
7185922 | Takayanagi et al. | Mar 2007 | B2 |
7220271 | Clubb et al. | May 2007 | B2 |
7226464 | Gamer et al. | Jun 2007 | B2 |
7229472 | DePalma et al. | Jun 2007 | B2 |
7241304 | Boyle et al. | Jul 2007 | B2 |
7288112 | Denardo et al. | Oct 2007 | B2 |
7300458 | Henkes et al. | Nov 2007 | B2 |
7306618 | Demond et al. | Dec 2007 | B2 |
7314483 | Landau et al. | Jan 2008 | B2 |
7316692 | Huffmaster | Jan 2008 | B2 |
7323001 | Clubb et al. | Jan 2008 | B2 |
7331976 | McGuckin, Jr. et al. | Feb 2008 | B2 |
7344550 | Carrison et al. | Mar 2008 | B2 |
7399308 | Borillo et al. | Jul 2008 | B2 |
7410491 | Hopkins et al. | Aug 2008 | B2 |
7425215 | Boyle et al. | Sep 2008 | B2 |
7452496 | Brady et al. | Nov 2008 | B2 |
7491215 | Vale et al. | Feb 2009 | B2 |
7491216 | Brady | Feb 2009 | B2 |
7510565 | Gilson et al. | Mar 2009 | B2 |
7534252 | Sepetka et al. | May 2009 | B2 |
7556636 | Mazzocchi et al. | Jul 2009 | B2 |
7582111 | Krolik et al. | Sep 2009 | B2 |
7594926 | Linder et al. | Sep 2009 | B2 |
7604649 | McGuckin, Jr. et al. | Oct 2009 | B2 |
7604650 | Bergheim | Oct 2009 | B2 |
7609649 | Bhandari et al. | Oct 2009 | B1 |
7618434 | Santa et al. | Nov 2009 | B2 |
7662165 | Gilson et al. | Feb 2010 | B2 |
7670356 | Mazzocchi et al. | Mar 2010 | B2 |
7678123 | Chanduszko | Mar 2010 | B2 |
7691121 | Rosenbluth et al. | Apr 2010 | B2 |
7691124 | Balgobin | Apr 2010 | B2 |
7708770 | Linder et al. | May 2010 | B2 |
7717929 | Fallman | May 2010 | B2 |
7736385 | Agnew | Jun 2010 | B2 |
7758606 | Streeter et al. | Jul 2010 | B2 |
7758611 | Kato | Jul 2010 | B2 |
7766934 | Pal et al. | Aug 2010 | B2 |
7771452 | Pal et al. | Aug 2010 | B2 |
7780694 | Palmer et al. | Aug 2010 | B2 |
7780700 | Frazier et al. | Aug 2010 | B2 |
7811305 | Balgobin et al. | Oct 2010 | B2 |
7815659 | Conlon et al. | Oct 2010 | B2 |
7819893 | Brady et al. | Oct 2010 | B2 |
7828815 | Mazzocchi et al. | Nov 2010 | B2 |
7828816 | Mazzocchi et al. | Nov 2010 | B2 |
7833240 | Okushi et al. | Nov 2010 | B2 |
7842053 | Chanduszko et al. | Nov 2010 | B2 |
7846175 | Bonnette et al. | Dec 2010 | B2 |
7846176 | Gilson et al. | Dec 2010 | B2 |
7850708 | Pal | Dec 2010 | B2 |
7883516 | Huang et al. | Feb 2011 | B2 |
7887560 | Kusleika | Feb 2011 | B2 |
7901426 | Gilson et al. | Mar 2011 | B2 |
7914549 | Morsi | Mar 2011 | B2 |
7922732 | Mazzocchi et al. | Apr 2011 | B2 |
7927784 | Simpson | Apr 2011 | B2 |
7931659 | Bose et al. | Apr 2011 | B2 |
7998165 | Huffmaster | Aug 2011 | B2 |
8002822 | Glocker et al. | Aug 2011 | B2 |
8021379 | Thompson et al. | Sep 2011 | B2 |
8021380 | Thompson et al. | Sep 2011 | B2 |
8043326 | Hancock et al. | Oct 2011 | B2 |
8048151 | OBrien et al. | Nov 2011 | B2 |
8052640 | Fiorella et al. | Nov 2011 | B2 |
8057497 | Raju et al. | Nov 2011 | B1 |
8057507 | Horan et al. | Nov 2011 | B2 |
8066757 | Ferrera et al. | Nov 2011 | B2 |
8070791 | Ferrera et al. | Dec 2011 | B2 |
8088140 | Ferrera et al. | Jan 2012 | B2 |
8100935 | Rosenbluth et al. | Jan 2012 | B2 |
8109941 | Richardson | Feb 2012 | B2 |
8118829 | Carrison et al. | Feb 2012 | B2 |
8118856 | Schreck et al. | Feb 2012 | B2 |
8123769 | Osborne | Feb 2012 | B2 |
8137377 | Palmer et al. | Mar 2012 | B2 |
8142422 | Makower et al. | Mar 2012 | B2 |
8142442 | Palmer et al. | Mar 2012 | B2 |
8182508 | Magnuson et al. | May 2012 | B2 |
8187298 | Pal | May 2012 | B2 |
8246641 | Osborne et al. | Aug 2012 | B2 |
8246672 | Osborne | Aug 2012 | B2 |
8252017 | Paul, Jr. et al. | Aug 2012 | B2 |
8252018 | Valaie | Aug 2012 | B2 |
8262689 | Schneiderman et al. | Sep 2012 | B2 |
8285668 | Kaiser | Oct 2012 | B2 |
8287538 | Brenzel et al. | Oct 2012 | B2 |
8298257 | Sepetka et al. | Oct 2012 | B2 |
RE43882 | Hopkins et al. | Dec 2012 | E |
8357178 | Grandfield et al. | Jan 2013 | B2 |
8357179 | Grandfield et al. | Jan 2013 | B2 |
8357180 | Feller, III et al. | Jan 2013 | B2 |
8357893 | Xu et al. | Jan 2013 | B2 |
8361095 | Osborne | Jan 2013 | B2 |
8361110 | Chanduszko | Jan 2013 | B2 |
8366663 | Fiorella et al. | Feb 2013 | B2 |
8409215 | Sepetka et al. | Apr 2013 | B2 |
8414482 | Belson | Apr 2013 | B2 |
8414543 | McGuckin, Jr. et al. | Apr 2013 | B2 |
8419748 | Valaie | Apr 2013 | B2 |
8460312 | Bose et al. | Jun 2013 | B2 |
8460313 | Huffmaster | Jun 2013 | B2 |
8486104 | Samson et al. | Jul 2013 | B2 |
8529596 | Grandfield et al. | Sep 2013 | B2 |
8545526 | Martin et al. | Oct 2013 | B2 |
8574262 | Ferrera et al. | Nov 2013 | B2 |
8574915 | Zhang et al. | Nov 2013 | B2 |
8579915 | French et al. | Nov 2013 | B2 |
8585713 | Ferrera et al. | Nov 2013 | B2 |
8608761 | Osborne et al. | Dec 2013 | B2 |
8679142 | Slee et al. | Mar 2014 | B2 |
8690907 | Janardhan | Apr 2014 | B1 |
8696622 | Fiorella et al. | Apr 2014 | B2 |
8702652 | Fiorella et al. | Apr 2014 | B2 |
8702704 | Shelton, IV et al. | Apr 2014 | B2 |
8702724 | Olsen et al. | Apr 2014 | B2 |
8777919 | Kimura et al. | Jul 2014 | B2 |
8777976 | Brady et al. | Jul 2014 | B2 |
8777979 | Shrivastava et al. | Jul 2014 | B2 |
8784434 | Rosenbluth et al. | Jul 2014 | B2 |
8784441 | Rosenbluth et al. | Jul 2014 | B2 |
8795305 | Martin et al. | Aug 2014 | B2 |
8795317 | Grandfield et al. | Aug 2014 | B2 |
8795345 | Grandfield et al. | Aug 2014 | B2 |
8814892 | Galdonik et al. | Aug 2014 | B2 |
8814925 | Hilaire et al. | Aug 2014 | B2 |
8852205 | Brady et al. | Oct 2014 | B2 |
8870941 | Evans et al. | Oct 2014 | B2 |
8900265 | Ulm, III | Dec 2014 | B1 |
8920358 | Levine et al. | Dec 2014 | B2 |
8939991 | Krolik et al. | Jan 2015 | B2 |
8945143 | Ferrera et al. | Feb 2015 | B2 |
8945160 | Krolik et al. | Feb 2015 | B2 |
8945169 | Pal | Feb 2015 | B2 |
8945172 | Ferrera et al. | Feb 2015 | B2 |
8956399 | Cam et al. | Feb 2015 | B2 |
8968330 | Rosenbluth et al. | Mar 2015 | B2 |
9011481 | Aggerholm et al. | Apr 2015 | B2 |
9039749 | Shrivastava et al. | May 2015 | B2 |
9072537 | Grandfield et al. | Jul 2015 | B2 |
9095342 | Becking et al. | Aug 2015 | B2 |
9113936 | Palmer et al. | Aug 2015 | B2 |
9119656 | Bose et al. | Sep 2015 | B2 |
9138307 | Valaie | Sep 2015 | B2 |
9155552 | Ulm, III | Oct 2015 | B2 |
9161758 | Figulla et al. | Oct 2015 | B2 |
9161766 | Slee et al. | Oct 2015 | B2 |
9173668 | Ulm, III | Nov 2015 | B2 |
9173688 | Dosta | Nov 2015 | B2 |
9186487 | Dubrul et al. | Nov 2015 | B2 |
9198687 | Fulkerson et al. | Dec 2015 | B2 |
9204887 | Cully et al. | Dec 2015 | B2 |
9211132 | Bowman | Dec 2015 | B2 |
9232992 | Heidner et al. | Jan 2016 | B2 |
9254371 | Martin et al. | Feb 2016 | B2 |
9301769 | Brady et al. | Apr 2016 | B2 |
9332999 | Ray et al. | May 2016 | B2 |
9402707 | Brady et al. | Aug 2016 | B2 |
9445829 | Brady et al. | Sep 2016 | B2 |
9456834 | Folk | Oct 2016 | B2 |
9532792 | Galdonik et al. | Jan 2017 | B2 |
9532873 | Kelley | Jan 2017 | B2 |
9533344 | Monetti et al. | Jan 2017 | B2 |
9539011 | Chen et al. | Jan 2017 | B2 |
9539022 | Bowman | Jan 2017 | B2 |
9539122 | Burke et al. | Jan 2017 | B2 |
9539382 | Nelson | Jan 2017 | B2 |
9549830 | Bruszewski et al. | Jan 2017 | B2 |
9554805 | Tompkins et al. | Jan 2017 | B2 |
9561125 | Bowman et al. | Feb 2017 | B2 |
9572982 | Burnes et al. | Feb 2017 | B2 |
9579104 | Beckham et al. | Feb 2017 | B2 |
9579484 | Barnell | Feb 2017 | B2 |
9585642 | Dinsmoor et al. | Mar 2017 | B2 |
9615832 | Bose et al. | Apr 2017 | B2 |
9615951 | Bennett et al. | Apr 2017 | B2 |
9622753 | Cox | Apr 2017 | B2 |
9636115 | Henry et al. | May 2017 | B2 |
9636439 | Chu et al. | May 2017 | B2 |
9642639 | Brady et al. | May 2017 | B2 |
9642675 | Werneth et al. | May 2017 | B2 |
9655633 | Leynov et al. | May 2017 | B2 |
9655645 | Staunton | May 2017 | B2 |
9655898 | Palepu et al. | May 2017 | B2 |
9655989 | Cruise et al. | May 2017 | B2 |
9662129 | Galdonik et al. | May 2017 | B2 |
9662238 | Dwork et al. | May 2017 | B2 |
9662425 | Lilja et al. | May 2017 | B2 |
9668898 | Wong | Jun 2017 | B2 |
9675477 | Thompson | Jun 2017 | B2 |
9675782 | Connolly | Jun 2017 | B2 |
9676022 | Ensign et al. | Jun 2017 | B2 |
9692557 | Murphy | Jun 2017 | B2 |
9693852 | Lam et al. | Jul 2017 | B2 |
9700262 | Janik et al. | Jul 2017 | B2 |
9700399 | Acosta-Acevedo | Jul 2017 | B2 |
9717421 | Griswold et al. | Aug 2017 | B2 |
9717500 | Tieu et al. | Aug 2017 | B2 |
9717502 | Teoh et al. | Aug 2017 | B2 |
9724103 | Cruise et al. | Aug 2017 | B2 |
9724526 | Strother et al. | Aug 2017 | B2 |
9750565 | Bloom et al. | Sep 2017 | B2 |
9757260 | Greenan | Sep 2017 | B2 |
9758606 | Lambert et al. | Sep 2017 | B2 |
9764111 | Gulachenski | Sep 2017 | B2 |
9770251 | Bowman et al. | Sep 2017 | B2 |
9770577 | Li et al. | Sep 2017 | B2 |
9775621 | Tompkins et al. | Oct 2017 | B2 |
9775706 | Peterson et al. | Oct 2017 | B2 |
9775732 | Khenansho | Oct 2017 | B2 |
9788800 | Mayoras, Jr. | Oct 2017 | B2 |
9795391 | Saatchi et al. | Oct 2017 | B2 |
9801980 | Karino et al. | Oct 2017 | B2 |
9808599 | Bowman et al. | Nov 2017 | B2 |
9833252 | Sepetka et al. | Dec 2017 | B2 |
9833304 | Horan et al. | Dec 2017 | B2 |
9833604 | Lam et al. | Dec 2017 | B2 |
9833625 | Waldhauser et al. | Dec 2017 | B2 |
9901434 | Hoffman | Feb 2018 | B2 |
9918720 | Marchand et al. | Mar 2018 | B2 |
9939361 | Gajji et al. | Apr 2018 | B2 |
10070878 | Ma | Sep 2018 | B2 |
10201360 | Vale et al. | Feb 2019 | B2 |
10292723 | Brady et al. | May 2019 | B2 |
10299811 | Brady et al. | May 2019 | B2 |
10363054 | Vale et al. | Jul 2019 | B2 |
10376274 | Farin et al. | Aug 2019 | B2 |
10390850 | Vale et al. | Aug 2019 | B2 |
10617435 | Vale et al. | Apr 2020 | B2 |
10722257 | Skillrud et al. | Jul 2020 | B2 |
20010001315 | Bates et al. | May 2001 | A1 |
20010016755 | Addis | Aug 2001 | A1 |
20010037141 | Yee et al. | Nov 2001 | A1 |
20010037171 | Sato | Nov 2001 | A1 |
20010041909 | Tsugita et al. | Nov 2001 | A1 |
20010049554 | Ruiz et al. | Dec 2001 | A1 |
20010051810 | Dubrul et al. | Dec 2001 | A1 |
20020004667 | Adams et al. | Jan 2002 | A1 |
20020016609 | Wensel et al. | Feb 2002 | A1 |
20020022859 | Hogendijk | Feb 2002 | A1 |
20020026211 | Khosravi et al. | Feb 2002 | A1 |
20020042627 | Brady et al. | Apr 2002 | A1 |
20020049468 | Streeter et al. | Apr 2002 | A1 |
20020052620 | Barbut | May 2002 | A1 |
20020058911 | Gilson et al. | May 2002 | A1 |
20020068954 | Foster | Jun 2002 | A1 |
20020072764 | Sepetka et al. | Jun 2002 | A1 |
20020082558 | Samson et al. | Jun 2002 | A1 |
20020091407 | Zadno-Azizi et al. | Jul 2002 | A1 |
20020095171 | Belef | Jul 2002 | A1 |
20020123765 | Sepetka et al. | Sep 2002 | A1 |
20020138094 | Borillo et al. | Sep 2002 | A1 |
20020143349 | Gifford, III et al. | Oct 2002 | A1 |
20020143362 | Macoviak et al. | Oct 2002 | A1 |
20020156455 | Barbut | Oct 2002 | A1 |
20020161393 | Demond et al. | Oct 2002 | A1 |
20020165576 | Boyle et al. | Nov 2002 | A1 |
20020173819 | Leeflang et al. | Nov 2002 | A1 |
20020183787 | Wahr et al. | Dec 2002 | A1 |
20020188276 | Evans et al. | Dec 2002 | A1 |
20020188314 | Anderson et al. | Dec 2002 | A1 |
20020193824 | Boylan et al. | Dec 2002 | A1 |
20020198588 | Armstrong et al. | Dec 2002 | A1 |
20030004536 | Boylan et al. | Jan 2003 | A1 |
20030004538 | Secrest et al. | Jan 2003 | A1 |
20030004540 | Linder et al. | Jan 2003 | A1 |
20030004542 | Wensel et al. | Jan 2003 | A1 |
20030009146 | Muni et al. | Jan 2003 | A1 |
20030009191 | Wensel et al. | Jan 2003 | A1 |
20030038447 | Cantele | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030050663 | Khachin et al. | Mar 2003 | A1 |
20030064151 | Klinedinst | Apr 2003 | A1 |
20030108224 | Ike | Jun 2003 | A1 |
20030114879 | Euteneuer et al. | Jun 2003 | A1 |
20030125798 | Martin | Jul 2003 | A1 |
20030130682 | Broome et al. | Jul 2003 | A1 |
20030144687 | Brady et al. | Jul 2003 | A1 |
20030144688 | Brady et al. | Jul 2003 | A1 |
20030153158 | Ho et al. | Aug 2003 | A1 |
20030153943 | Michael et al. | Aug 2003 | A1 |
20030153944 | Phung et al. | Aug 2003 | A1 |
20030163064 | Vrba et al. | Aug 2003 | A1 |
20030163158 | White | Aug 2003 | A1 |
20030171769 | Barbut | Sep 2003 | A1 |
20030171771 | Anderson et al. | Sep 2003 | A1 |
20030176884 | Berrada et al. | Sep 2003 | A1 |
20030187495 | Cully et al. | Oct 2003 | A1 |
20030195537 | Dubrul et al. | Oct 2003 | A1 |
20030195554 | Shen et al. | Oct 2003 | A1 |
20030199917 | Knudson et al. | Oct 2003 | A1 |
20030204202 | Palmer et al. | Oct 2003 | A1 |
20030208224 | Broome | Nov 2003 | A1 |
20030212430 | Bose et al. | Nov 2003 | A1 |
20030236533 | Wilson et al. | Dec 2003 | A1 |
20040064179 | Linder et al. | Apr 2004 | A1 |
20040068288 | Palmer et al. | Apr 2004 | A1 |
20040073243 | Sepetka et al. | Apr 2004 | A1 |
20040079429 | Miller et al. | Apr 2004 | A1 |
20040082962 | Demarais et al. | Apr 2004 | A1 |
20040082967 | Broome et al. | Apr 2004 | A1 |
20040088001 | Bosma et al. | May 2004 | A1 |
20040093065 | Yachia et al. | May 2004 | A1 |
20040098050 | Foerster et al. | May 2004 | A1 |
20040133231 | Maitland et al. | Jul 2004 | A1 |
20040133232 | Rosenbluth et al. | Jul 2004 | A1 |
20040138692 | Phung et al. | Jul 2004 | A1 |
20040153118 | Clubb et al. | Aug 2004 | A1 |
20040199201 | Kellett et al. | Oct 2004 | A1 |
20040215318 | Kwitkin | Oct 2004 | A1 |
20040220663 | Rivelli | Nov 2004 | A1 |
20050033248 | Machida et al. | Feb 2005 | A1 |
20050033348 | Sepetka et al. | Feb 2005 | A1 |
20050038447 | Huffmaster | Feb 2005 | A1 |
20050038468 | Panetta et al. | Feb 2005 | A1 |
20050043759 | Chanduszko | Feb 2005 | A1 |
20050049619 | Sepetka et al. | Mar 2005 | A1 |
20050049669 | Jones et al. | Mar 2005 | A1 |
20050049670 | Jones et al. | Mar 2005 | A1 |
20050055033 | Leslie et al. | Mar 2005 | A1 |
20050055047 | Greenhalgh | Mar 2005 | A1 |
20050058837 | Farnworth et al. | Mar 2005 | A1 |
20050059995 | Sepetka et al. | Mar 2005 | A1 |
20050085849 | Sepetka et al. | Apr 2005 | A1 |
20050090779 | Osypka | Apr 2005 | A1 |
20050090857 | Kusleika et al. | Apr 2005 | A1 |
20050125024 | Sepetka et al. | Jun 2005 | A1 |
20050149997 | Wolozin et al. | Jul 2005 | A1 |
20050171566 | Kanamaru | Aug 2005 | A1 |
20050173135 | Almen | Aug 2005 | A1 |
20050192627 | Whisenant et al. | Sep 2005 | A1 |
20050216030 | Sepetka et al. | Sep 2005 | A1 |
20050216050 | Sepetka et al. | Sep 2005 | A1 |
20050228417 | Teitelbaum et al. | Oct 2005 | A1 |
20050251206 | Maahs et al. | Nov 2005 | A1 |
20050251209 | Saadat et al. | Nov 2005 | A1 |
20050267491 | Kellett et al. | Dec 2005 | A1 |
20050273135 | Chanduszko et al. | Dec 2005 | A1 |
20050288686 | Sepetka et al. | Dec 2005 | A1 |
20060008332 | Greenberg et al. | Jan 2006 | A1 |
20060009798 | Callister et al. | Jan 2006 | A1 |
20060009799 | Kleshinski et al. | Jan 2006 | A1 |
20060020286 | Niermann | Jan 2006 | A1 |
20060030877 | Martinez et al. | Feb 2006 | A1 |
20060041228 | Vo et al. | Feb 2006 | A1 |
20060058836 | Bose et al. | Mar 2006 | A1 |
20060058837 | Bose et al. | Mar 2006 | A1 |
20060058838 | Bose et al. | Mar 2006 | A1 |
20060064151 | Guterman et al. | Mar 2006 | A1 |
20060069424 | Acosta et al. | Mar 2006 | A1 |
20060074477 | Berthiaume et al. | Apr 2006 | A1 |
20060149313 | Arguello et al. | Jul 2006 | A1 |
20060155305 | Freudenthal et al. | Jul 2006 | A1 |
20060161187 | Levine et al. | Jul 2006 | A1 |
20060195137 | Sepetka et al. | Aug 2006 | A1 |
20060224177 | Finitsis | Oct 2006 | A1 |
20060224179 | Kucharczyk et al. | Oct 2006 | A1 |
20060229638 | Abrams et al. | Oct 2006 | A1 |
20060235501 | Igaki | Oct 2006 | A1 |
20060241677 | Johnson et al. | Oct 2006 | A1 |
20060282111 | Morsi | Dec 2006 | A1 |
20060287668 | Fawzi et al. | Dec 2006 | A1 |
20060287701 | Pal | Dec 2006 | A1 |
20060293706 | Shimon | Dec 2006 | A1 |
20070010857 | Sugimoto et al. | Jan 2007 | A1 |
20070032879 | Levine et al. | Feb 2007 | A1 |
20070088382 | Bei et al. | Apr 2007 | A1 |
20070088383 | Pal et al. | Apr 2007 | A1 |
20070118173 | Magnuson et al. | May 2007 | A1 |
20070149997 | Muller | Jun 2007 | A1 |
20070156170 | Hancock et al. | Jul 2007 | A1 |
20070165170 | Fukuda | Jul 2007 | A1 |
20070179527 | Eskuri et al. | Aug 2007 | A1 |
20070191866 | Palmer et al. | Aug 2007 | A1 |
20070198028 | Miloslayski et al. | Aug 2007 | A1 |
20070198051 | Clubb et al. | Aug 2007 | A1 |
20070198075 | Levy | Aug 2007 | A1 |
20070208367 | Fiorella et al. | Sep 2007 | A1 |
20070208371 | French et al. | Sep 2007 | A1 |
20070225749 | Martin et al. | Sep 2007 | A1 |
20070233175 | Zaver et al. | Oct 2007 | A1 |
20070244505 | Gilson et al. | Oct 2007 | A1 |
20070270902 | Slazas et al. | Nov 2007 | A1 |
20070288054 | Tanaka et al. | Dec 2007 | A1 |
20080045881 | Teitelbaum et al. | Feb 2008 | A1 |
20080077227 | Ouellette et al. | Mar 2008 | A1 |
20080082107 | Miller et al. | Apr 2008 | A1 |
20080086190 | Ta | Apr 2008 | A1 |
20080091223 | Pokorney et al. | Apr 2008 | A1 |
20080097386 | Osypka | Apr 2008 | A1 |
20080109031 | Sepetka et al. | May 2008 | A1 |
20080109032 | Sepetka et al. | May 2008 | A1 |
20080119886 | Greenhalgh et al. | May 2008 | A1 |
20080177296 | Sepetka et al. | Jul 2008 | A1 |
20080178890 | Townsend et al. | Jul 2008 | A1 |
20080183197 | Sepetka et al. | Jul 2008 | A1 |
20080183198 | Sepetka et al. | Jul 2008 | A1 |
20080183205 | Sepetka et al. | Jul 2008 | A1 |
20080188876 | Sepetka et al. | Aug 2008 | A1 |
20080188885 | Sepetka et al. | Aug 2008 | A1 |
20080188887 | Batiste | Aug 2008 | A1 |
20080200946 | Braun et al. | Aug 2008 | A1 |
20080200947 | Kusleika et al. | Aug 2008 | A1 |
20080215077 | Sepetka et al. | Sep 2008 | A1 |
20080221600 | Dieck et al. | Sep 2008 | A1 |
20080228209 | DeMello et al. | Sep 2008 | A1 |
20080234706 | Sepetka et al. | Sep 2008 | A1 |
20080243170 | Jenson et al. | Oct 2008 | A1 |
20080255596 | Jenson et al. | Oct 2008 | A1 |
20080262528 | Martin | Oct 2008 | A1 |
20080262532 | Martin | Oct 2008 | A1 |
20080269871 | Eli | Oct 2008 | A1 |
20080275488 | Fleming | Nov 2008 | A1 |
20080275493 | Farmiga | Nov 2008 | A1 |
20080281350 | Sepetka et al. | Nov 2008 | A1 |
20080312681 | Ansel et al. | Dec 2008 | A1 |
20090005858 | Young et al. | Jan 2009 | A1 |
20090024157 | Anukhin | Jan 2009 | A1 |
20090030443 | Buser et al. | Jan 2009 | A1 |
20090062841 | Amplatz et al. | Mar 2009 | A1 |
20090069828 | Martin et al. | Mar 2009 | A1 |
20090076539 | Valaie | Mar 2009 | A1 |
20090088793 | Bagaoisan et al. | Apr 2009 | A1 |
20090088795 | Cahill | Apr 2009 | A1 |
20090105722 | Fulkerson et al. | Apr 2009 | A1 |
20090105737 | Fulkerson et al. | Apr 2009 | A1 |
20090105747 | Chanduszko et al. | Apr 2009 | A1 |
20090149881 | Vale et al. | Jun 2009 | A1 |
20090163851 | Holloway et al. | Jun 2009 | A1 |
20090177206 | Lozier et al. | Jul 2009 | A1 |
20090182336 | Brenzel et al. | Jul 2009 | A1 |
20090281610 | Parker | Nov 2009 | A1 |
20090281619 | Le et al. | Nov 2009 | A1 |
20090292297 | Ferrere | Nov 2009 | A1 |
20090292307 | Razack | Nov 2009 | A1 |
20090299393 | Martin et al. | Dec 2009 | A1 |
20090299403 | Chanduszko et al. | Dec 2009 | A1 |
20090306702 | Miloslayski et al. | Dec 2009 | A1 |
20090326636 | Hashimoto et al. | Dec 2009 | A1 |
20100004607 | Wilson et al. | Jan 2010 | A1 |
20100076482 | Shu et al. | Mar 2010 | A1 |
20100087850 | Razack | Apr 2010 | A1 |
20100087908 | Hilaire et al. | Apr 2010 | A1 |
20100114017 | Lenker et al. | May 2010 | A1 |
20100125326 | Kalstad et al. | May 2010 | A1 |
20100125327 | Agnew | May 2010 | A1 |
20100191272 | Keating | Jul 2010 | A1 |
20100211094 | Sargent, Jr. | Aug 2010 | A1 |
20100268264 | Bonnette et al. | Oct 2010 | A1 |
20100268265 | Krolik et al. | Oct 2010 | A1 |
20100274277 | Eaton | Oct 2010 | A1 |
20100318178 | Rapaport et al. | Dec 2010 | A1 |
20100324649 | Mattsson et al. | Dec 2010 | A1 |
20100331949 | Habib | Dec 2010 | A1 |
20110009875 | Grandfield et al. | Jan 2011 | A1 |
20110009940 | Grandfield et al. | Jan 2011 | A1 |
20110022149 | Cox et al. | Jan 2011 | A1 |
20110054504 | Porter | Mar 2011 | A1 |
20110054514 | Arcand et al. | Mar 2011 | A1 |
20110054516 | Keegan et al. | Mar 2011 | A1 |
20110060212 | Slee et al. | Mar 2011 | A1 |
20110060359 | Hannes et al. | Mar 2011 | A1 |
20110106137 | Shimon | May 2011 | A1 |
20110125181 | Brady et al. | May 2011 | A1 |
20110152920 | Eckhouse et al. | Jun 2011 | A1 |
20110160763 | Ferrera et al. | Jun 2011 | A1 |
20110166586 | Sepetka et al. | Jul 2011 | A1 |
20110196414 | Porter et al. | Aug 2011 | A1 |
20110202088 | Eckhouse et al. | Aug 2011 | A1 |
20110208233 | McGuckin, Jr. et al. | Aug 2011 | A1 |
20110213297 | Aklog et al. | Sep 2011 | A1 |
20110213393 | Aklog et al. | Sep 2011 | A1 |
20110213403 | Aboytes | Sep 2011 | A1 |
20110224707 | Miloslayski et al. | Sep 2011 | A1 |
20110276120 | Gilson et al. | Nov 2011 | A1 |
20120041449 | Eckhouse et al. | Feb 2012 | A1 |
20120041474 | Eckhouse et al. | Feb 2012 | A1 |
20120059356 | di Palma et al. | Mar 2012 | A1 |
20120083823 | Shrivastava et al. | Apr 2012 | A1 |
20120083868 | Shrivastava et al. | Apr 2012 | A1 |
20120089216 | Rapaport et al. | Apr 2012 | A1 |
20120101510 | Lenker et al. | Apr 2012 | A1 |
20120123466 | Porter et al. | May 2012 | A1 |
20120143237 | Cam et al. | Jun 2012 | A1 |
20120150147 | Leynov et al. | Jun 2012 | A1 |
20120165858 | Eckhouse et al. | Jun 2012 | A1 |
20120165859 | Eckhouse et al. | Jun 2012 | A1 |
20120209312 | Aggerholm et al. | Aug 2012 | A1 |
20120215250 | Grandfield et al. | Aug 2012 | A1 |
20120277788 | Cattaneo | Nov 2012 | A1 |
20120283768 | Cox et al. | Nov 2012 | A1 |
20120296362 | Cam et al. | Nov 2012 | A1 |
20120316600 | Ferrera et al. | Dec 2012 | A1 |
20120330350 | Jones et al. | Dec 2012 | A1 |
20130030460 | Marks et al. | Jan 2013 | A1 |
20130030461 | Marks et al. | Jan 2013 | A1 |
20130046330 | McIntosh et al. | Feb 2013 | A1 |
20130046333 | Jones et al. | Feb 2013 | A1 |
20130046334 | Jones et al. | Feb 2013 | A1 |
20130116774 | Strauss et al. | May 2013 | A1 |
20130131614 | Hassan et al. | May 2013 | A1 |
20130144311 | Fung et al. | Jun 2013 | A1 |
20130144326 | Brady et al. | Jun 2013 | A1 |
20130158592 | Porter | Jun 2013 | A1 |
20130184739 | Brady et al. | Jul 2013 | A1 |
20130197567 | Brady et al. | Aug 2013 | A1 |
20130226146 | Tekulve | Aug 2013 | A1 |
20130268050 | Wilson et al. | Oct 2013 | A1 |
20130271788 | Utsunomiya | Oct 2013 | A1 |
20130277079 | Tsuzuki et al. | Oct 2013 | A1 |
20130281788 | Garrison | Oct 2013 | A1 |
20130325051 | Martin et al. | Dec 2013 | A1 |
20130325055 | Eckhouse et al. | Dec 2013 | A1 |
20130325056 | Eckhouse et al. | Dec 2013 | A1 |
20130345739 | Brady et al. | Dec 2013 | A1 |
20140046359 | Bowman et al. | Feb 2014 | A1 |
20140121672 | Folk | May 2014 | A1 |
20140128905 | Molaei | May 2014 | A1 |
20140135812 | Divino et al. | May 2014 | A1 |
20140180377 | Bose et al. | Jun 2014 | A1 |
20140180397 | Gerberding et al. | Jun 2014 | A1 |
20140183077 | Rosendall et al. | Jul 2014 | A1 |
20140194911 | Johnson et al. | Jul 2014 | A1 |
20140194919 | Losordo et al. | Jul 2014 | A1 |
20140200607 | Sepetka et al. | Jul 2014 | A1 |
20140200608 | Brady | Jul 2014 | A1 |
20140236220 | Inoue | Aug 2014 | A1 |
20140257362 | Eidenschink | Sep 2014 | A1 |
20140276922 | McLain et al. | Sep 2014 | A1 |
20140277079 | Vale et al. | Sep 2014 | A1 |
20140303667 | Cox | Oct 2014 | A1 |
20140309657 | Ben-Ami | Oct 2014 | A1 |
20140309673 | Dacuycuy et al. | Oct 2014 | A1 |
20140330302 | Tekulve et al. | Nov 2014 | A1 |
20140343585 | Ferrera et al. | Nov 2014 | A1 |
20140371769 | Vale et al. | Dec 2014 | A1 |
20140371779 | Vale | Dec 2014 | A1 |
20140371780 | Vale et al. | Dec 2014 | A1 |
20140372779 | Wong et al. | Dec 2014 | A1 |
20140379023 | Brady et al. | Dec 2014 | A1 |
20150018859 | Quick et al. | Jan 2015 | A1 |
20150018860 | Quick et al. | Jan 2015 | A1 |
20150032144 | Holloway | Jan 2015 | A1 |
20150080937 | Davidson | Mar 2015 | A1 |
20150112376 | Molaei et al. | Apr 2015 | A1 |
20150133990 | Davidson | May 2015 | A1 |
20150150672 | Ma | Jun 2015 | A1 |
20150164523 | Brady et al. | Jun 2015 | A1 |
20150250497 | Marks et al. | Sep 2015 | A1 |
20150257775 | Gilvarry et al. | Sep 2015 | A1 |
20150272716 | Pinchuk | Oct 2015 | A1 |
20150297252 | Miloslavski et al. | Oct 2015 | A1 |
20150313617 | Grandfield et al. | Nov 2015 | A1 |
20150320431 | Ulm | Nov 2015 | A1 |
20150352325 | Quick | Dec 2015 | A1 |
20150359547 | Vale et al. | Dec 2015 | A1 |
20150366650 | Zi | Dec 2015 | A1 |
20150374391 | Quick et al. | Dec 2015 | A1 |
20150374393 | Brady et al. | Dec 2015 | A1 |
20150374479 | Vale | Dec 2015 | A1 |
20160015402 | Brady et al. | Jan 2016 | A1 |
20160022269 | Ganske et al. | Jan 2016 | A1 |
20160022296 | Brady et al. | Jan 2016 | A1 |
20160045298 | Thinnes, Jr. et al. | Feb 2016 | A1 |
20160066921 | Seifert et al. | Mar 2016 | A1 |
20160106448 | Brady et al. | Apr 2016 | A1 |
20160106449 | Brady et al. | Apr 2016 | A1 |
20160113663 | Brady et al. | Apr 2016 | A1 |
20160113664 | Brady et al. | Apr 2016 | A1 |
20160113665 | Brady et al. | Apr 2016 | A1 |
20160120558 | Brady et al. | May 2016 | A1 |
20160143653 | Vale et al. | May 2016 | A1 |
20160192953 | Brady et al. | Jul 2016 | A1 |
20160192954 | Brady et al. | Jul 2016 | A1 |
20160192955 | Brady et al. | Jul 2016 | A1 |
20160192956 | Brady et al. | Jul 2016 | A1 |
20160256180 | Vale et al. | Sep 2016 | A1 |
20160303381 | Pierce | Oct 2016 | A1 |
20160317168 | Brady et al. | Nov 2016 | A1 |
20170007264 | Cruise et al. | Jan 2017 | A1 |
20170007265 | Guo et al. | Jan 2017 | A1 |
20170020542 | Martin | Jan 2017 | A1 |
20170020670 | Murray et al. | Jan 2017 | A1 |
20170020700 | Bienvenu et al. | Jan 2017 | A1 |
20170027640 | Kunis et al. | Feb 2017 | A1 |
20170027692 | Bonhoeffer et al. | Feb 2017 | A1 |
20170027725 | Argentine | Feb 2017 | A1 |
20170035436 | Morita | Feb 2017 | A1 |
20170035567 | Duffy | Feb 2017 | A1 |
20170042548 | Lam | Feb 2017 | A1 |
20170049596 | Schabert | Feb 2017 | A1 |
20170071614 | Vale et al. | Mar 2017 | A1 |
20170071737 | Kelley | Mar 2017 | A1 |
20170072452 | Monetti et al. | Mar 2017 | A1 |
20170079671 | Morero et al. | Mar 2017 | A1 |
20170079680 | Bowman | Mar 2017 | A1 |
20170079766 | Wang et al. | Mar 2017 | A1 |
20170079767 | Leon-Yip | Mar 2017 | A1 |
20170079812 | Lam et al. | Mar 2017 | A1 |
20170079817 | Sepetka et al. | Mar 2017 | A1 |
20170079819 | Pung et al. | Mar 2017 | A1 |
20170079820 | Lam et al. | Mar 2017 | A1 |
20170086851 | Wallace et al. | Mar 2017 | A1 |
20170086862 | Vale et al. | Mar 2017 | A1 |
20170086863 | Brady et al. | Mar 2017 | A1 |
20170086996 | Peterson et al. | Mar 2017 | A1 |
20170095259 | Tompkins et al. | Apr 2017 | A1 |
20170100126 | Bowman et al. | Apr 2017 | A1 |
20170100141 | Morero et al. | Apr 2017 | A1 |
20170100143 | Grandfield | Apr 2017 | A1 |
20170100183 | Iaizzo et al. | Apr 2017 | A1 |
20170105743 | Vale et al. | Apr 2017 | A1 |
20170112515 | Brady et al. | Apr 2017 | A1 |
20170112647 | Sachar et al. | Apr 2017 | A1 |
20170113023 | Steingisser et al. | Apr 2017 | A1 |
20170119409 | Ma | May 2017 | A1 |
20170147765 | Mehta | May 2017 | A1 |
20170150979 | Ulm | Jun 2017 | A1 |
20170151032 | Loisel | Jun 2017 | A1 |
20170165062 | Rothstein | Jun 2017 | A1 |
20170165065 | Rothstein et al. | Jun 2017 | A1 |
20170165454 | Tuohy et al. | Jun 2017 | A1 |
20170172581 | Bose et al. | Jun 2017 | A1 |
20170172766 | Vong et al. | Jun 2017 | A1 |
20170172772 | Khenansho | Jun 2017 | A1 |
20170189033 | Sepetka et al. | Jul 2017 | A1 |
20170189035 | Porter | Jul 2017 | A1 |
20170215902 | Leynov et al. | Aug 2017 | A1 |
20170216484 | Cruise et al. | Aug 2017 | A1 |
20170224350 | Shimizu et al. | Aug 2017 | A1 |
20170224355 | Bowman et al. | Aug 2017 | A1 |
20170224467 | Piccagli et al. | Aug 2017 | A1 |
20170224511 | Dwork et al. | Aug 2017 | A1 |
20170224953 | Tran et al. | Aug 2017 | A1 |
20170231749 | Perkins et al. | Aug 2017 | A1 |
20170252064 | Staunton | Sep 2017 | A1 |
20170265983 | Lam et al. | Sep 2017 | A1 |
20170281192 | Tieu et al. | Oct 2017 | A1 |
20170281331 | Perkins et al. | Oct 2017 | A1 |
20170281344 | Costello | Oct 2017 | A1 |
20170281909 | Northrop et al. | Oct 2017 | A1 |
20170281912 | Melder et al. | Oct 2017 | A1 |
20170290593 | Cruise et al. | Oct 2017 | A1 |
20170290654 | Sethna | Oct 2017 | A1 |
20170296324 | Argentine | Oct 2017 | A1 |
20170296325 | Marrocco et al. | Oct 2017 | A1 |
20170303939 | Greenhalgh et al. | Oct 2017 | A1 |
20170303942 | Greenhalgh et al. | Oct 2017 | A1 |
20170303947 | Greenhalgh et al. | Oct 2017 | A1 |
20170303948 | Wallace et al. | Oct 2017 | A1 |
20170304041 | Argentine | Oct 2017 | A1 |
20170304097 | Corwin et al. | Oct 2017 | A1 |
20170304595 | Nagasrinivasa et al. | Oct 2017 | A1 |
20170312109 | Le | Nov 2017 | A1 |
20170312484 | Shipley et al. | Nov 2017 | A1 |
20170316561 | Helm et al. | Nov 2017 | A1 |
20170319826 | Bowman et al. | Nov 2017 | A1 |
20170333228 | Orth et al. | Nov 2017 | A1 |
20170333236 | Greenan | Nov 2017 | A1 |
20170333678 | Bowman et al. | Nov 2017 | A1 |
20170340383 | Bloom et al. | Nov 2017 | A1 |
20170348014 | Wallace et al. | Dec 2017 | A1 |
20170348514 | Guyon et al. | Dec 2017 | A1 |
20180263650 | Iwanami et al. | Sep 2018 | A1 |
20190000492 | Casey et al. | Jan 2019 | A1 |
20190167284 | Friedman et al. | Jun 2019 | A1 |
20190374239 | Martin et al. | Dec 2019 | A1 |
20190380723 | Grandfield et al. | Dec 2019 | A1 |
20190388097 | Girdhar et al. | Dec 2019 | A1 |
20200100804 | Casey et al. | Apr 2020 | A1 |
Number | Date | Country |
---|---|---|
2557083 | Jun 2003 | CN |
101172051 | May 2008 | CN |
102307613 | Jan 2012 | CN |
102596098 | Jul 2012 | CN |
104042304 | Sep 2014 | CN |
105662532 | Jun 2016 | CN |
205359559 | Jul 2016 | CN |
107530090 | Jan 2018 | CN |
202009001951 | Apr 2010 | DE |
102009056450 | Jun 2011 | DE |
102010010849 | Sep 2011 | DE |
102010014778 | Oct 2011 | DE |
102010024085 | Dec 2011 | DE |
102011014586 | Sep 2012 | DE |
2301450 | Mar 2011 | EP |
2438891 | Apr 2012 | EP |
2628455 | Aug 2013 | EP |
3156004 | Apr 2017 | EP |
2427554 | Jan 2007 | GB |
2494820 | Mar 2013 | GB |
H0919438 | Jan 1997 | JP |
2014511223 | May 2014 | JP |
2014525796 | Oct 2014 | JP |
2019-526365 | Sep 2019 | JP |
9424926 | Nov 1994 | WO |
9727808 | Aug 1997 | WO |
9738631 | Oct 1997 | WO |
9920335 | Apr 1999 | WO |
9956801 | Nov 1999 | WO |
9960933 | Dec 1999 | WO |
0121077 | Mar 2001 | WO |
0202162 | Jan 2002 | WO |
0211627 | Feb 2002 | WO |
0243616 | Jun 2002 | WO |
02070061 | Sep 2002 | WO |
02094111 | Nov 2002 | WO |
03002006 | Jan 2003 | WO |
03030751 | Apr 2003 | WO |
03051448 | Jun 2003 | WO |
2004028571 | Apr 2004 | WO |
2004056275 | Jul 2004 | WO |
2005000130 | Jan 2005 | WO |
2005027779 | Mar 2005 | WO |
2006021407 | Mar 2006 | WO |
2006031410 | Mar 2006 | WO |
2006107641 | Oct 2006 | WO |
2006135823 | Dec 2006 | WO |
2007054307 | May 2007 | WO |
2007068424 | Jun 2007 | WO |
2008034615 | Mar 2008 | WO |
2008051431 | May 2008 | WO |
2008131116 | Oct 2008 | WO |
2008135823 | Nov 2008 | WO |
2009031338 | Mar 2009 | WO |
2009076482 | Jun 2009 | WO |
2009086482 | Jul 2009 | WO |
2009105710 | Aug 2009 | WO |
2010010545 | Jan 2010 | WO |
2010046897 | Apr 2010 | WO |
2010075565 | Jul 2010 | WO |
2010102307 | Sep 2010 | WO |
2010146581 | Dec 2010 | WO |
2011013556 | Feb 2011 | WO |
2011066961 | Jun 2011 | WO |
2011082319 | Jul 2011 | WO |
2011095352 | Aug 2011 | WO |
2011106426 | Sep 2011 | WO |
2011110316 | Sep 2011 | WO |
2011135556 | Nov 2011 | WO |
2012052982 | Apr 2012 | WO |
2012064726 | May 2012 | WO |
2012081020 | Jun 2012 | WO |
2012110619 | Aug 2012 | WO |
2012120490 | Sep 2012 | WO |
WO-2012120490 | Sep 2012 | WO |
2012156924 | Nov 2012 | WO |
2013016435 | Jan 2013 | WO |
2013072777 | May 2013 | WO |
2013105099 | Jul 2013 | WO |
2013109756 | Jul 2013 | WO |
2013187927 | Dec 2013 | WO |
2014047650 | Mar 2014 | WO |
2014081892 | May 2014 | WO |
2014139845 | Sep 2014 | WO |
2014169266 | Oct 2014 | WO |
2014178198 | Nov 2014 | WO |
2015061365 | Apr 2015 | WO |
2015103547 | Jul 2015 | WO |
2015134625 | Sep 2015 | WO |
2015179324 | Nov 2015 | WO |
2015189354 | Dec 2015 | WO |
2016010995 | Jan 2016 | WO |
2016089451 | Jun 2016 | WO |
2017089424 | Jan 2017 | WO |
2017089424 | Jun 2017 | WO |
Entry |
---|
US 6,348,062 B1, 02/2002, Hopkins et al. (withdrawn) |
Communication pursuant to Article 94(3) EPC issued in corresponding European Patent Application No. 17 764 364.0 dated Mar. 9, 2020. |
International Search Report and Written Opinion issued for corresponding International Application No. PCT/EP2017/072030 dated Apr. 9, 2018. |
Chinese Search Report issued in corresponding Chinese Patent Application No. 201780068422.4 dated Dec. 30, 2020. Filed with English Translation. |
Search Report issued in corresponding Chinese Patent Application No. 201680080064.4 dated Jun. 9, 2020 (English translation only). |
Notification of Reasons for Refusal issued in corresponding Japanese Design Patent Application No. 2020-027634 dated Jun. 1, 2021, English translation only. |
Number | Date | Country | |
---|---|---|---|
20200305900 A1 | Oct 2020 | US |
Number | Date | Country | |
---|---|---|---|
62383905 | Sep 2016 | US |